A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses

Giorgio Bogani, Elena Tagliabue, Mauro Signorelli, Antonino Ditto, Fabio Martinelli, Valentina Chiappa, Lavinia Mosca, Ilaria Sabatucci, Umberto Leone Roberti Maggiore, Domenica Lorusso, Francesco Raspagliesi

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To test the applicability of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Memorial Sloan Kettering (MSK) criteria in predicting complete cytoreduction (CC) in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer (ROC).

METHODS: Data of consecutive patients undergoing SCS were reviewed. The Arbeitsgemeinschaft Gynäkologische Onkologie OVARian cancer study group (AGO-OVAR) and MSK criteria were retrospectively applied. Nomograms, based on AGO criteria, MSK criteria and both AGO and MSK criteria were built in order to assess the probability to achieve CC at SCS.

RESULTS: Overall, 194 patients met the inclusion criteria. CC was achieved in 161 (82.9%) patients. According to the AGO-OVAR criteria, we observed that CC was achieved in 87.0% of patients with positive AGO score. However, 45 out of 71 (63.4%) patients who did not fulfilled the AGO score had CC. Similarly, CC was achieved in 87.1%, 61.9% and 66.7% of patients for whom SCS was recommended, had to be considered and was not recommended, respectively. In order to evaluate the predictive value of the AGO-OVAR and MSK criteria we built 2 separate nomograms (c-index: 0.5900 and 0.5989, respectively) to test the probability to achieve CC at SCS. Additionally, we built a nomogram using both the aforementioned criteria (c-index: 0.5857).

CONCLUSION: The AGO and MSK criteria help identifying patients deserving SCS. However, these criteria might be strict, thus prohibiting a beneficial treatment in patients who do not met these criteria. Further studies are needed to clarify factors predicting CC at SCS.

Original languageEnglish
Pages (from-to)e40
JournalJournal of Gynecologic Oncology
Volume29
Issue number3
DOIs
Publication statusPublished - May 2018

Fingerprint

Nomograms
Ovarian Neoplasms

Cite this

@article{89b21fa8314843279345f090797da9e7,
title = "A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses",
abstract = "OBJECTIVE: To test the applicability of the Arbeitsgemeinschaft Gyn{\"a}kologische Onkologie (AGO) and Memorial Sloan Kettering (MSK) criteria in predicting complete cytoreduction (CC) in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer (ROC).METHODS: Data of consecutive patients undergoing SCS were reviewed. The Arbeitsgemeinschaft Gyn{\"a}kologische Onkologie OVARian cancer study group (AGO-OVAR) and MSK criteria were retrospectively applied. Nomograms, based on AGO criteria, MSK criteria and both AGO and MSK criteria were built in order to assess the probability to achieve CC at SCS.RESULTS: Overall, 194 patients met the inclusion criteria. CC was achieved in 161 (82.9{\%}) patients. According to the AGO-OVAR criteria, we observed that CC was achieved in 87.0{\%} of patients with positive AGO score. However, 45 out of 71 (63.4{\%}) patients who did not fulfilled the AGO score had CC. Similarly, CC was achieved in 87.1{\%}, 61.9{\%} and 66.7{\%} of patients for whom SCS was recommended, had to be considered and was not recommended, respectively. In order to evaluate the predictive value of the AGO-OVAR and MSK criteria we built 2 separate nomograms (c-index: 0.5900 and 0.5989, respectively) to test the probability to achieve CC at SCS. Additionally, we built a nomogram using both the aforementioned criteria (c-index: 0.5857).CONCLUSION: The AGO and MSK criteria help identifying patients deserving SCS. However, these criteria might be strict, thus prohibiting a beneficial treatment in patients who do not met these criteria. Further studies are needed to clarify factors predicting CC at SCS.",
author = "Giorgio Bogani and Elena Tagliabue and Mauro Signorelli and Antonino Ditto and Fabio Martinelli and Valentina Chiappa and Lavinia Mosca and Ilaria Sabatucci and {Leone Roberti Maggiore}, Umberto and Domenica Lorusso and Francesco Raspagliesi",
note = "Copyright {\circledC} 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.",
year = "2018",
month = "5",
doi = "10.3802/jgo.2018.29.e40",
language = "English",
volume = "29",
pages = "e40",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "3",

}

TY - JOUR

T1 - A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery

T2 - predictors- and nomogram-based analyses

AU - Bogani, Giorgio

AU - Tagliabue, Elena

AU - Signorelli, Mauro

AU - Ditto, Antonino

AU - Martinelli, Fabio

AU - Chiappa, Valentina

AU - Mosca, Lavinia

AU - Sabatucci, Ilaria

AU - Leone Roberti Maggiore, Umberto

AU - Lorusso, Domenica

AU - Raspagliesi, Francesco

N1 - Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.

PY - 2018/5

Y1 - 2018/5

N2 - OBJECTIVE: To test the applicability of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Memorial Sloan Kettering (MSK) criteria in predicting complete cytoreduction (CC) in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer (ROC).METHODS: Data of consecutive patients undergoing SCS were reviewed. The Arbeitsgemeinschaft Gynäkologische Onkologie OVARian cancer study group (AGO-OVAR) and MSK criteria were retrospectively applied. Nomograms, based on AGO criteria, MSK criteria and both AGO and MSK criteria were built in order to assess the probability to achieve CC at SCS.RESULTS: Overall, 194 patients met the inclusion criteria. CC was achieved in 161 (82.9%) patients. According to the AGO-OVAR criteria, we observed that CC was achieved in 87.0% of patients with positive AGO score. However, 45 out of 71 (63.4%) patients who did not fulfilled the AGO score had CC. Similarly, CC was achieved in 87.1%, 61.9% and 66.7% of patients for whom SCS was recommended, had to be considered and was not recommended, respectively. In order to evaluate the predictive value of the AGO-OVAR and MSK criteria we built 2 separate nomograms (c-index: 0.5900 and 0.5989, respectively) to test the probability to achieve CC at SCS. Additionally, we built a nomogram using both the aforementioned criteria (c-index: 0.5857).CONCLUSION: The AGO and MSK criteria help identifying patients deserving SCS. However, these criteria might be strict, thus prohibiting a beneficial treatment in patients who do not met these criteria. Further studies are needed to clarify factors predicting CC at SCS.

AB - OBJECTIVE: To test the applicability of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Memorial Sloan Kettering (MSK) criteria in predicting complete cytoreduction (CC) in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer (ROC).METHODS: Data of consecutive patients undergoing SCS were reviewed. The Arbeitsgemeinschaft Gynäkologische Onkologie OVARian cancer study group (AGO-OVAR) and MSK criteria were retrospectively applied. Nomograms, based on AGO criteria, MSK criteria and both AGO and MSK criteria were built in order to assess the probability to achieve CC at SCS.RESULTS: Overall, 194 patients met the inclusion criteria. CC was achieved in 161 (82.9%) patients. According to the AGO-OVAR criteria, we observed that CC was achieved in 87.0% of patients with positive AGO score. However, 45 out of 71 (63.4%) patients who did not fulfilled the AGO score had CC. Similarly, CC was achieved in 87.1%, 61.9% and 66.7% of patients for whom SCS was recommended, had to be considered and was not recommended, respectively. In order to evaluate the predictive value of the AGO-OVAR and MSK criteria we built 2 separate nomograms (c-index: 0.5900 and 0.5989, respectively) to test the probability to achieve CC at SCS. Additionally, we built a nomogram using both the aforementioned criteria (c-index: 0.5857).CONCLUSION: The AGO and MSK criteria help identifying patients deserving SCS. However, these criteria might be strict, thus prohibiting a beneficial treatment in patients who do not met these criteria. Further studies are needed to clarify factors predicting CC at SCS.

U2 - 10.3802/jgo.2018.29.e40

DO - 10.3802/jgo.2018.29.e40

M3 - Article

C2 - 29533023

VL - 29

SP - e40

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 3

ER -